Venous Thromboembolism
Perspectives
Withholding anticoagulation for isolated subsegmental pulmonary embolism – Houston, we have a problem
Feature
CVS Caremark formulary change freezes out apixaban
The decision doesn’t affect patients on a Medicare or Medicaid plan but hits those taking the popular anticoagulant who have select commercial...
From the Journals
D-dimer thresholds rule out PE in meta-analysis
Data from a large review support use of D-dimer levels to diagnose PE without imaging.
From the Journals
Apixaban outmatches rivaroxaban for VTE in study
These real-world findings may guide selection of initial anticoagulant therapy, according to authors of the paper.
From the Journals
D-dimer unreliable for ruling out pulmonary embolism in COVID-19
From the Journals
Refined heart rate cutoffs may improve prognostic value of acute PE scoring systems
In an observational registry-based study, dropping the 110-bpm heart rate threshold improved sensitivity for low-risk PE, while increasing it...
From the Journals
Prophylactic anticoagulation tied to lower death rate in COVID
Prophylactic use of low-dose anticoagulation to prevent venous thromboembolism was associated with reduced 60-day mortality in patients...
From the Journals
Study suggests no added risk of blood clots in COVID-19 outpatients
From the Journals
New ASH guidelines: VTE prevention and treatment in cancer patients
Opinion
ASH guidelines for venous thromboembolism: What family physicians need to know
A recommendation regarding the use of DOACs may ease some of the burden of monitoring patients on long-term Coumadin.